Omniox is pioneering the development of its H-NOX platform technology, which focuses on creating innovative oxygen delivery vehicles known as OMX biologics. These biologics are specifically engineered to address significant unmet medical needs by safely delivering oxygen to hypoxic tissues—areas of the body where oxygen levels are abnormally low and contribute to disease progression. By targeting these hypoxic regions, OMX biologics aim to restore normal tissue function, potentially leading to improved patient outcomes and even cures for various conditions.

The H-NOX technology is characterized by its unique, stable, and non-reactive heme-binding proteins that can be tailored to meet different physiological oxygen requirements. The design of OMX products allows for optimal efficacy, with specific circulation half-lives and tissue penetration profiles. A key advantage of these products is their ability to retain oxygen until they reach hypoxic microenvironments, in contrast to red blood cells, which release oxygen prematurely at normal venous oxygen levels. This targeted delivery mechanism enhances the therapeutic potential of OMX biologics in treating diseases associated with low oxygen availability.

United States

Biotherapeutics for ischemic, hypoxic, and anemic diseases in Ischemic, cardiovascular and stroke diseases, oncology, diabetes, trauma, surgery, and sickle cell crises.

Omniox

Company Details